Fibrogen Inc CS (FGEN)

$17.20 1.52 (8.10%)

15:52 EDT FGEN Stock Quote Delayed 30 Minutes

7 Unknown Biotech Stocks That Could Rocket in 2023

By Faisal Humayun, InvestorPlace Contributor Sep 23, 2022

Unknown biotech stocks that are poised for a big rally in 2023. Emerging biotech companies with a promising clinical pipeline.

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday

Today’s Biggest Pre-Market Movers: 10 Top Gainers and Losers on Wednesday Morning

Volume:

Previous Close -

Market Cap 1.68B

PE Ratio -5.24

EPS -3.28

Volume (Avg. Vol.) 1.68M

Day's Range $16.42 - $18.62

52-Week Range $8.67 - $25.69

Dividend & Yield N/A (N/A)

FGEN Stock Predictions, Articles, and Fibrogen Inc CS News

From InvestorPlace
From the Web

7 Big Biotech Stocks to Avoid

By Louis Navellier, Editor, Growth Investor Jan 28, 2020

The only thing more important than what to buy is what not to buy. These biotech stocks are at the top of the avoid list. Here's why.

FibroGen News: Why FGEN Stock Is Plummeting Today

By William White, InvestorPlace Writer May 10, 2019

FibroGen news has FGEN stock down on Friday after releasing confusing results from a recent trial for its kidney disease drug.

Mizuho: 7 Long-Term Value Stocks to Buy Now

By Harriet Lefton, Writer, TipRanks Jan 14, 2019

Mizuho Securities has challenged each analyst to select long-term stocks that can provide value. Here are 7 of their top stock picks.

FibroGen raised to buy by Stifel ahead of Phase 3 data for pamrevlumab (FGEN)

From Seeking Alpha Jun 2, 2023

FibroGen (FGEN) stock has been upgraded to buy by Stifel ahead of the expected release of data from two Phase 3 studies for its drug pamrevlumab. Read more here.

FibroGen stock rises after roxadustat matches Sepo in Chinese trial

From Seeking Alpha May 18, 2023

FibroGen's (FGEN) oral drug roxadustat was good as recombinant erythropoietin alfa ((SEPO)) in improving hemoglobin level. Read more here

FibroGen gets $150M term-loan financing (NASDAQ:FGEN)

From Seeking Alpha May 1, 2023

FibroGen (FGEN) announces a term loan facility with investment funds managed by Morgan Stanley Tactical Value or MSTV of up to $150M.The $150M term loan facility will be available to...

Why did Sarepta Therapeutics Stock Plummet?

From MarketBeat Mar 21, 2023

SRPT stock fell 20% after the FDA changed course on their new DMD treatment approval. The stock remains strong with an encouraging outlook and a mod Buy rating.

FibroGen's Earnings: A Preview

From Benzinga Feb 25, 2022

FibroGen (NASDAQ:FGEN) is set to give its latest quarterly earnings report on Monday, 2022-02-28. Here's what investors need to know before the announcement. Analysts estimate...

FibroGen GAAP EPS of -$0.70 beats by $0.25, revenue of $34.37M beats by $10.42M (NASDAQ:FGEN)

From Seeking Alpha Feb 27, 2023

FibroGen press release (FGEN): Q4 GAAP EPS of -$0.70 beats by $0.25.Revenue of $34.37M (+107.8% Y/Y) beats by $10.42M.

Fibrogen Inc CS (FGEN)

7 Unknown Biotech Stocks That Could Rocket in 2023

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday

Today’s Biggest Pre-Market Movers: 10 Top Gainers and Losers on Wednesday Morning

11 Best Stocks to Buy for 2023

Louis Navellier's Total Grade

Is ? a BUY?

Louis Navellier's Total Grade

Louis Navellier's Total Grade

Fundamental Grade

Quantitative Grade

Fibrogen Inc CS (FGEN)

11 Best Stocks to Buy for 2023

Louis Navellier's Total Grade

Is ? a BUY?

Louis Navellier's Total Grade

Louis Navellier's Total Grade

Fundamental Grade

Quantitative Grade

FGEN Stock Predictions, Articles, and Fibrogen Inc CS News

Subscriber Sign in